FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2128713083> ?p ?o ?g. }

• W2128713083 endingPage "163" @default.
• W2128713083 startingPage "155" @default.
• W2128713083 abstract "Graves' ophthalmopathy (GO) is characterized by expanded volume of the orbital tissues associated with elevated serum levels of TSH receptor (TSHR) autoantibodies. Because previous studies have demonstrated evidence of adipogenesis within the GO orbit, we sought to determine whether M22, a human monoclonal antibody directed against TSHR, enhances adipogenesis in orbital fibroblasts from patients with GO and, if so, to identify signaling mechanisms involved. GO orbital fibroblast cultures (n=10) were treated for 10 days with bovine TSH (1 or 10.0 U/l) or M22 (1 or 10 ng/ml) in serum-free adipocyte differentiation medium. Some cultures also received a phosphoinositide 3-kinase (PI3K) inhibitor or an inhibitor of cAMP production. In other experiments, confluent cultures (n=8) were treated for between 1 and 30 min with TSH (0.1–10.0 U/l) or M22 (0.1–100 ng/ml) with measurement of cAMP production or levels of phosphorylated AKT (pAKT). We found levels of adiponectin, leptin, and TSHR mRNA to be increased in GO cultures treated for 10 days with either M22 (2.6 mean fold ±0.7; P=0.03) or TSH (13.2±5.8-fold, P=0.048). In other studies, M22 and TSH stimulated cAMP production and pAKT levels in GO cells. Inhibition of PI3K activity during 10 days in culture decreased the levels of M22-stimulated mRNA encoding adiponectin (67±12%; P=0.021), as well as adiponectin and CCAAT/enhancer-binding protein α protein levels. In conclusion, M22 is a pro-adipogenic factor in GO orbital preadipocytes. This antibody appears to act via the PI3K signaling cascade, suggesting that inhibition of PI3K signaling may represent a potential novel therapeutic approach in GO." @default.
• W2128713083 created "2016-06-24" @default.
• W2128713083 creator A5024225278 @default.
• W2128713083 creator A5039851000 @default.
• W2128713083 creator A5041657790 @default.
• W2128713083 creator A5046989093 @default.
• W2128713083 creator A5091104216 @default.
• W2128713083 date "2011-02-14" @default.
• W2128713083 modified "2023-09-28" @default.
• W2128713083 title "A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy" @default.
• W2128713083 cites W1484058370 @default.
• W2128713083 cites W1856370030 @default.
• W2128713083 cites W1907219612 @default.
• W2128713083 cites W1964878444 @default.
• W2128713083 cites W1973225811 @default.
• W2128713083 cites W1980611859 @default.
• W2128713083 cites W1980632651 @default.
• W2128713083 cites W1989294105 @default.
• W2128713083 cites W1993242643 @default.
• W2128713083 cites W2019699942 @default.
• W2128713083 cites W2030897875 @default.
• W2128713083 cites W2034161190 @default.
• W2128713083 cites W2049828925 @default.
• W2128713083 cites W2056815794 @default.
• W2128713083 cites W2059992589 @default.
• W2128713083 cites W2063294738 @default.
• W2128713083 cites W2063823126 @default.
• W2128713083 cites W2069519523 @default.
• W2128713083 cites W2084872482 @default.
• W2128713083 cites W2086892531 @default.
• W2128713083 cites W2094147091 @default.
• W2128713083 cites W2106957229 @default.
• W2128713083 cites W2108967017 @default.
• W2128713083 cites W2109005905 @default.
• W2128713083 cites W2109007966 @default.
• W2128713083 cites W2123670278 @default.
• W2128713083 cites W2133470303 @default.
• W2128713083 cites W2163219777 @default.
• W2128713083 cites W2168389240 @default.
• W2128713083 cites W2170434318 @default.
• W2128713083 doi "https://doi.org/10.1530/jme-11-0006" @default.
• W2128713083 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3074639" @default.
• W2128713083 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21321093" @default.
• W2128713083 hasPublicationYear "2011" @default.
• W2128713083 type Work @default.
• W2128713083 sameAs 2128713083 @default.
• W2128713083 citedByCount "110" @default.
• W2128713083 countsByYear W21287130832012 @default.
• W2128713083 countsByYear W21287130832013 @default.
• W2128713083 countsByYear W21287130832014 @default.
• W2128713083 countsByYear W21287130832015 @default.
• W2128713083 countsByYear W21287130832016 @default.
• W2128713083 countsByYear W21287130832017 @default.
• W2128713083 countsByYear W21287130832018 @default.
• W2128713083 countsByYear W21287130832019 @default.
• W2128713083 countsByYear W21287130832020 @default.
• W2128713083 countsByYear W21287130832021 @default.
• W2128713083 countsByYear W21287130832022 @default.
• W2128713083 countsByYear W21287130832023 @default.
• W2128713083 crossrefType "journal-article" @default.
• W2128713083 hasAuthorship W2128713083A5024225278 @default.
• W2128713083 hasAuthorship W2128713083A5039851000 @default.
• W2128713083 hasAuthorship W2128713083A5041657790 @default.
• W2128713083 hasAuthorship W2128713083A5046989093 @default.
• W2128713083 hasAuthorship W2128713083A5091104216 @default.
• W2128713083 hasBestOaLocation W21287130831 @default.
• W2128713083 hasConcept C122927707 @default.
• W2128713083 hasConcept C126322002 @default.
• W2128713083 hasConcept C134018914 @default.
• W2128713083 hasConcept C170493617 @default.
• W2128713083 hasConcept C171089720 @default.
• W2128713083 hasConcept C184235292 @default.
• W2128713083 hasConcept C185592680 @default.
• W2128713083 hasConcept C2776782570 @default.
• W2128713083 hasConcept C2777391703 @default.
• W2128713083 hasConcept C2779306644 @default.
• W2128713083 hasConcept C55493867 @default.
• W2128713083 hasConcept C62478195 @default.
• W2128713083 hasConcept C71924100 @default.
• W2128713083 hasConcept C75217442 @default.
• W2128713083 hasConcept C97029542 @default.
• W2128713083 hasConceptScore W2128713083C122927707 @default.
• W2128713083 hasConceptScore W2128713083C126322002 @default.
• W2128713083 hasConceptScore W2128713083C134018914 @default.
• W2128713083 hasConceptScore W2128713083C170493617 @default.
• W2128713083 hasConceptScore W2128713083C171089720 @default.
• W2128713083 hasConceptScore W2128713083C184235292 @default.
• W2128713083 hasConceptScore W2128713083C185592680 @default.
• W2128713083 hasConceptScore W2128713083C2776782570 @default.
• W2128713083 hasConceptScore W2128713083C2777391703 @default.
• W2128713083 hasConceptScore W2128713083C2779306644 @default.
• W2128713083 hasConceptScore W2128713083C55493867 @default.
• W2128713083 hasConceptScore W2128713083C62478195 @default.
• W2128713083 hasConceptScore W2128713083C71924100 @default.
• W2128713083 hasConceptScore W2128713083C75217442 @default.
• W2128713083 hasConceptScore W2128713083C97029542 @default.
• W2128713083 hasIssue "3" @default.
• W2128713083 hasLocation W21287130831 @default.

• next